Physician profile
Isha Gupta
NPI 1922345008
$41,615.47
in general payments reported to CMS, 2019-2025
48 companies · $35K in 2025
The $35K reported for 2025 was more than what 98% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,175 · 2020: $431 · 2021: $906 · 2022: $1,621 · 2023: $911 · 2024: $1,973 · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Travel and Lodging: $6,309 · Food and Beverage: $4,576 · Education: $716.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,880.63 |
| Travel and Lodging | $6,308.91 |
| Food and Beverage | $4,576.49 |
| Education | $715.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $33,281.60 | 2019-2025 | Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,570.60 | 2019-2025 | Farxiga, Lokelma, Breztri |
| Mallinckrodt Hospital Products INC. | $835.76 | 2021-2025 | Acthar, Terlivaz |
| Bayer Healthcare Pharmaceuticals INC. | $690.06 | 2021-2025 | |
| Opko Pharmaceuticals, LLC | $631.28 | 2020-2025 | Rayaldee |
| Glaxosmithkline, LLC. | $534.96 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Aurinia Pharma U.S., INC. | $424.42 | 2021-2024 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $373.45 | 2019-2025 | Jynarque, Rexulti, Voyxact |
| Mallinckrodt Enterprises LLC | $305.54 | 2019 | |
| Vifor Pharma, INC. | $286.48 | 2019-2025 | Veltassa |
| Calliditas Therapeutics US INC. | $229.26 | 2022-2025 | Tarpeyo |
| Horizon Therapeutics Plc | $204.26 | 2019-2023 | Krystexxa |
| Travere Therapeutics, INC. | $199.86 | 2023-2025 | |
| Pfizer INC. | $161.02 | 2019-2025 | |
| Akebia Therapeutics INC | $150.16 | 2019 |
Show all 47 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isha Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.